Prostaglandin Analog Compounds for Glaucoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma and ocular hypertension lack effective compounds that can be administered topically to the eye to provide therapeutic benefits while maintaining comfort and stability.
Innovation Solution
A compound with a specific chemical structure, including various organic acid functional groups, amides, esters, and tetrazolyl functional groups, is administered as a medicament or composition, either alone or in combination with other drugs, to treat glaucoma and ocular hypertension, formulated as a liquid for topical application.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for glaucoma are used, then therapeutic benefits are provided, but the treatments lack effectiveness when administered topically and do not maintain comfort and stability
Solution Approach 1:
The patent modifies the chemical structure of prostaglandin analogs by introducing specific substituents at positions 1, 3, and 9 of the cyclopentane ring, as well as modifications to the side chains. These structural parameter changes enhance the compound's stability and therapeutic effectiveness while maintaining compatibility with topical administration, directly resolving the contradiction between reliability and ease of operation.
Solution Approach 2:
The patent creates composite chemical structures by combining modified prostaglandin cores with specific functional groups including tetrazolyl, fluorinated, and cyanomethyl substituents. These composite structures provide both the therapeutic effectiveness needed for glaucoma treatment and the stability required for comfortable topical administration, addressing both aspects of the contradiction simultaneously.
2Ease of operation
If current treatments are administered topically, then some therapeutic benefit is achieved, but stability and comfort are not maintained
Solution Approach 1:
The patent introduces specific chemical modifications including fluorine atoms at position 3, tetrazolyl groups at position 1, and cyanomethyl substituents at position 9 of the prostaglandin structure. These parameter changes in the molecular structure enhance the compound's metabolic stability and resistance to degradation, ensuring formulation stability is maintained during topical administration while preserving ease of operation.
3Reliability
If existing glaucoma medications are used, then treatment is provided, but they lack the combination of efficacy, comfort, and stability
Solution Approach 1:
The patent employs systematic modifications to the prostaglandin molecular parameters, including introduction of electron-withdrawing groups (fluorine, cyano), aromatic substituents (tetrazolyl), and specific side chain configurations. These parameter changes increase the pharmacological potency of the compound, allowing effective glaucoma treatment at lower dosages, thereby simultaneously improving therapeutic efficacy while reducing the quantity of substance required.
Data Source
AI summary
Compound having the formula below are disclosed herein: formula (I). Therapeutic methods, compositions, and medicaments related thereto are also disclosed.